Exelixis holder plans Rule 144 sale of 3,856 shares

Exelixis Inc. has a shareholder planning to sell restricted shares under Rule 144.

Accepted by SEC EDGAR 02/13/2026 - 04:39 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Exelixis Inc. has a shareholder planning to sell restricted shares under Rule 144. The notice covers 3,856 shares of Exelixis common stock to be sold through UBS Financial Services on NASDAQ, with an approximate aggregate market value of $165,383.84. These shares were acquired as restricted stock units from the issuer on 01/05/2026, the same date listed as the payment date. The filing also reports that Exelixis had 259,708,689 shares of common stock outstanding, providing context for the size of this planned sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for EXEL disclose?

The Form 144 discloses a planned sale of 3,856 Exelixis common shares under Rule 144. The shares were acquired as restricted stock units and will be sold on NASDAQ through UBS Financial Services, with an aggregate market value of $165,383.84.

How many EXEL shares are planned to be sold under this Form 144?

The filing covers a proposed sale of 3,856 shares of Exelixis common stock. These shares are to be sold on NASDAQ via UBS Financial Services and were originally acquired as restricted stock units from the issuer on 01/05/2026.

What is the approximate value of the EXEL shares in this Rule 144 notice?

The Form 144 lists an aggregate market value of $165,383.84 for the 3,856 Exelixis common shares. This value reflects the estimated market price of the shares to be sold through UBS Financial Services on NASDAQ.

When were the EXEL shares being sold under Form 144 acquired?

The Exelixis shares were acquired on 01/05/2026 as a restricted stock unit grant from the issuer. The filing also shows 01/05/2026 as the date of payment, with the nature of payment described as N/A, consistent with equity compensation.

On which exchange will the EXEL Form 144 shares be sold?

The planned sale of 3,856 Exelixis common shares is listed for execution on the NASDAQ exchange. UBS Financial Services, based at 11 Madison Avenue in New York, is named as the broker handling the transaction for this Rule 144 notice.

How many EXEL shares were outstanding compared to the Form 144 amount?

The filing reports 259,708,689 Exelixis common shares outstanding at the time of the notice. The planned Rule 144 sale of 3,856 shares is small relative to this total, offering context on the scale of the proposed transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001823769
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	EXELIXIS, INC.
SEC File Number	000-30235
Address of Issuer	1851 HARBOR BAY PARKWAY ALAMEDA CALIFORNIA 94502
Phone	6508377000
Name of Person for Whose Account the Securities are To Be Sold	Eckhardt Sue Gail
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	3856	165383.84	259708689	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/05/2026	Restricted Stock Unit	Issuer			3856	01/05/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for S. Gail Eckhardt
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)